Patents Assigned to Hanlim Pharmaceutical Co., Ltd.
-
Patent number: 11771647Abstract: The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.Type: GrantFiled: February 18, 2019Date of Patent: October 3, 2023Assignee: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Dong-Yeop Shin, Hu-Seong Kim, Geun-Hyeog Lee, Kyung-Joon Kim, Yun-Seok Cho, Mi-Jin O, Mi-Jung Kim
-
Patent number: 11299478Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.Type: GrantFiled: March 20, 2019Date of Patent: April 12, 2022Assignee: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Kyung-Hee Kim, Jung-Wook Chin, Ji-Hoon Lee, Shin-Ae Kim, Kyung-Jin Jung, Jun-Woo Kim, Sang-Hyun Min, Ji-Hoon Yu, Ju-Suk Lee, Won-Seok Lee, Jae-Young Song, Eung-Seok Lee, Tae-Cheon Jeong, Jung-Ae Kim
-
Publication number: 20210047301Abstract: Provided is a 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The 2-cyanopyrimidin-4-yl carbamate or urea derivative or pharmaceutically acceptable salt thereof selectively inhibits cathepsin K and therefore can be usefully applied for preventing or treating osteoporosis.Type: ApplicationFiled: March 20, 2019Publication date: February 18, 2021Applicant: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Kyung-Hee KIM, Jung-Wook CHIN, Ji-Hoon LEE, Shin-Ae KIM, Kyung-Jin JUNG, Jun-Woo KIM, Sang-Hyun MIN, Ji-Hoon YU, Ju-Suk LEE, Won-Seok LEE, Jae-Young SONG, Eung-Seok LEE, Tae-Cheon JEONG, Jung-Ae KIM
-
Publication number: 20200405634Abstract: The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.Type: ApplicationFiled: February 18, 2019Publication date: December 31, 2020Applicant: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Dong-Yeop SHIN, Hu-Seong KIM, Geun-Hyeog LEE, Kyung-Joon KIM, Yun-Seok CHO, Mi-Jin O, Mi-Jung KIM
-
Patent number: 10487074Abstract: The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.Type: GrantFiled: November 24, 2016Date of Patent: November 26, 2019Assignee: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Jae-Chun Ryu, Yong-Kyun Park, Hyun-Kyu Kim, Dong-Yeop Shin
-
Publication number: 20190248768Abstract: The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.Type: ApplicationFiled: November 24, 2016Publication date: August 15, 2019Applicant: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Jae-Chun RYU, Yong-Kyun PARK, Hyun-Kyu KIM, Dong-Yeop SHIN
-
Patent number: 9301954Abstract: The present invention provides a method for preventing or treating osteoarthritis comprising administrating rebamipide or a pharmaceutical composition comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier to a subject in need thereof. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: GrantFiled: March 4, 2011Date of Patent: April 5, 2016Assignees: HANLIM PHARMACEUTICAL CO., LTD, CATHOLIC UNIVERSITY ACADEMIC COOPERATION FOUNDATIONInventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Young-Ok Jung, Geun-Hyeog Lee, Byong-Sun Choi, Jin-Ha Park, Eun-Young Kwak
-
Patent number: 8859531Abstract: The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.Type: GrantFiled: November 18, 2011Date of Patent: October 14, 2014Assignee: Hanlim Pharmaceutical Co., LtdInventors: Sang-Yong Lee, Geun-Hyeog Lee, Byong-Sun Choi, Jong-Hyeon Ryu, Jin-Ha Park, Mi-Jin O
-
Patent number: 8691842Abstract: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: GrantFiled: October 8, 2009Date of Patent: April 8, 2014Assignees: Catholic University Industry Academic Cooperation Foundation, Hanlim Pharmaceutical Co., Ltd.Inventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Joo-Yeon Jhun, Geun-Hyeog Lee, Se-Wan Park, Jin-Ha Park, Eun-Young Kwak
-
Publication number: 20130252929Abstract: The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.Type: ApplicationFiled: November 18, 2011Publication date: September 26, 2013Applicant: HANLIM PHARMACEUTICAL CO., LTD.Inventors: Sang-Yong Lee, Geun-Hyeog Lee, Byong-Sun Choi, Jong-Hyeon Ryu, Jin-Ha Park, Mi-Jin O.
-
Publication number: 20120172394Abstract: The present invention provides a pharmaceutical composition for preventing or treating rheumatoid arthritis comprising rebamipide as an active ingredient and a pharmaceutically acceptable carrier. The pharmaceutical composition may be for oral administration, for example an oral solid dosage form of a tablet or capsule form. The pharmaceutical composition may be formulated into a unit dosage form suitable for orally administering rebamipide in a dose ranging from 0.5 to 50 mg/kg, preferably from 0.6 to 6 mg/kg.Type: ApplicationFiled: October 8, 2009Publication date: July 5, 2012Applicants: HANLIM PHARMACEUTICAL CO., LTD., CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Jun-Ki Min, Mi-La Cho, Yun-Ju Woo, Hye-Jwa Oh, Joo-Yeon Jhun, Geun-Hyeog Lee, Se-Wan Park, Jin-Ha Park, Eun-Young Kwak
-
Patent number: 7579475Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.Type: GrantFiled: August 21, 2007Date of Patent: August 25, 2009Assignee: Hanlim Pharmaceutical Co., Ltd.Inventors: You Sup Chung, Mun Choun Ha
-
Patent number: 7482464Abstract: Provided is a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.Type: GrantFiled: February 28, 2007Date of Patent: January 27, 2009Assignee: Hanlim Pharmaceutical Co., Ltd.Inventors: You Sup Chung, Mun Choun Ha
-
Publication number: 20080027227Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.Type: ApplicationFiled: August 21, 2007Publication date: January 31, 2008Applicant: Hanlim Pharmaceutical Co., Ltd.Inventors: You Chung, Mun Ha
-
Patent number: 7279492Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.Type: GrantFiled: September 8, 2003Date of Patent: October 9, 2007Assignee: Hanlim Pharmaceutical Co., Ltd.Inventors: You Sup Chung, Mun Choun Ha
-
Publication number: 20070155969Abstract: Provided is a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.Type: ApplicationFiled: February 28, 2007Publication date: July 5, 2007Applicant: Hanlim Pharmaceutical Co., Ltd.Inventors: You Chung, Mun Ha
-
Publication number: 20060014795Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.Type: ApplicationFiled: September 8, 2003Publication date: January 19, 2006Applicant: Hanlim Pharmaceutical Co., Ltd.Inventors: You Chung, Mun Choun Ha
-
Publication number: 20060014961Abstract: The present invention provides a process for the preparation of S-(?)-amlodipine from (R,S)-amlodipine in industrial-scale using L-(+)-tartaric acid, which is much cheaper than D-(?)-tartaric acid.Type: ApplicationFiled: September 8, 2003Publication date: January 19, 2006Applicant: HANLIM PHARMACEUTICAL CO., LTD.Inventors: You Chung, Mun Ha
-
Patent number: D768492Type: GrantFiled: November 12, 2014Date of Patent: October 11, 2016Assignee: HANLIM PHARMACEUTICAL CO., LTD.Inventor: Jung Jin Kim